Invention Grant
US08852936B2 Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
有权
自体淋巴结转移与VEGF-C或VEGF-D生长因子治疗联合治疗淋巴水肿并改善重建手术
- Patent Title: Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
- Patent Title (中): 自体淋巴结转移与VEGF-C或VEGF-D生长因子治疗联合治疗淋巴水肿并改善重建手术
-
Application No.: US13624145Application Date: 2012-09-21
-
Publication No.: US08852936B2Publication Date: 2014-10-07
- Inventor: Anne Saaristo , Kari Alitalo
- Applicant: Laurantis Pharma Oy
- Applicant Address: FI Turku
- Assignee: Laurantis Pharma Oy
- Current Assignee: Laurantis Pharma Oy
- Current Assignee Address: FI Turku
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Main IPC: C12N5/071
- IPC: C12N5/071 ; A61F2/00

Abstract:
Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.
Public/Granted literature
Information query